Nature Communications (Mar 2023)
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
- Brian C. Sanders,
- Suman Pokhrel,
- Audrey D. Labbe,
- Irimpan I. Mathews,
- Connor J. Cooper,
- Russell B. Davidson,
- Gwyndalyn Phillips,
- Kevin L. Weiss,
- Qiu Zhang,
- Hugh O’Neill,
- Manat Kaur,
- Jurgen G. Schmidt,
- Walter Reichard,
- Surekha Surendranathan,
- Jyothi Parvathareddy,
- Lexi Phillips,
- Christopher Rainville,
- David E. Sterner,
- Desigan Kumaran,
- Babak Andi,
- Gyorgy Babnigg,
- Nigel W. Moriarty,
- Paul D. Adams,
- Andrzej Joachimiak,
- Brett L. Hurst,
- Suresh Kumar,
- Tauseef R. Butt,
- Colleen B. Jonsson,
- Lori Ferrins,
- Soichi Wakatsuki,
- Stephanie Galanie,
- Martha S. Head,
- Jerry M. Parks
Affiliations
- Brian C. Sanders
- Biosciences Division, Oak Ridge National Laboratory
- Suman Pokhrel
- Department of Chemical and Systems Biology, Stanford University School of Medicine
- Audrey D. Labbe
- Biosciences Division, Oak Ridge National Laboratory
- Irimpan I. Mathews
- Stanford Synchrotron Radiation Lightsource
- Connor J. Cooper
- Biosciences Division, Oak Ridge National Laboratory
- Russell B. Davidson
- Biosciences Division, Oak Ridge National Laboratory
- Gwyndalyn Phillips
- Neutron Scattering Division, Oak Ridge National Laboratory
- Kevin L. Weiss
- Neutron Scattering Division, Oak Ridge National Laboratory
- Qiu Zhang
- Neutron Scattering Division, Oak Ridge National Laboratory
- Hugh O’Neill
- Neutron Scattering Division, Oak Ridge National Laboratory
- Manat Kaur
- Department of Structural Biology, Stanford University School of Medicine
- Jurgen G. Schmidt
- B-11 Bioenergy and Biome Sciences, Bioscience Division, Los Alamos National Laboratory
- Walter Reichard
- Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center
- Surekha Surendranathan
- Regional Biocontainment Laboratory, University of Tennessee Health Science Center
- Jyothi Parvathareddy
- Regional Biocontainment Laboratory, University of Tennessee Health Science Center
- Lexi Phillips
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University
- Christopher Rainville
- Progenra Inc.
- David E. Sterner
- Progenra Inc.
- Desigan Kumaran
- Biology Department, Brookhaven National Laboratory
- Babak Andi
- Center for BioMolecular Structure, National Synchrotron Light Source II, Brookhaven National Laboratory
- Gyorgy Babnigg
- Center for Structural Genomics of Infectious Diseases, Consortium for Advanced Science and Engineering, University of Chicago
- Nigel W. Moriarty
- Molecular Biosciences and Integrated Bioimaging, Lawrence Berkeley National Laboratory
- Paul D. Adams
- Molecular Biosciences and Integrated Bioimaging, Lawrence Berkeley National Laboratory
- Andrzej Joachimiak
- Center for Structural Genomics of Infectious Diseases, Consortium for Advanced Science and Engineering, University of Chicago
- Brett L. Hurst
- Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University
- Suresh Kumar
- Progenra Inc.
- Tauseef R. Butt
- Progenra Inc.
- Colleen B. Jonsson
- Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center
- Lori Ferrins
- Department of Chemistry and Chemical Biology, Northeastern University
- Soichi Wakatsuki
- Department of Chemical and Systems Biology, Stanford University School of Medicine
- Stephanie Galanie
- Biosciences Division, Oak Ridge National Laboratory
- Martha S. Head
- Joint Institute for Biological Sciences, Oak Ridge National Laboratory
- Jerry M. Parks
- Biosciences Division, Oak Ridge National Laboratory
- DOI
- https://doi.org/10.1038/s41467-023-37254-w
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 17
Abstract
The development of direct-acting antivirals to combat COVID-19 remains an important goal. Here the authors design covalent inhibitors that target the papain-like protease from SARS-CoV-2. The most promising inhibitor blocks viral replication in mammalian cells.
